2 g/ dl) hos de patienter, der fik MIRCERA, og hos dem, der fik I undersøgelserne darbepoetin alfa. af patienter, der i forvejen fik medicin for at stimulere dannelsen af røde blodlegemer, holdt hæmoglobinindholdet sig lige så godt hos de patienter, der skiftede til MIRCERA, som hos dem, der fortsatte med uændret medicin.
In the studies of patients who had already been receiving medicines to stimulate red blood cell production, patients who changed to MIRCERA maintained their haemoglobin levels as effectively as the patients who remained on their existing medicines.